Revolutionizing sepsis detection for early intervention

Loop Diagnostics is a biotech company that develops a diagnostic tool for sepsis, using an in vitro cellular immunoassay to detect it within the first hour of bloodstream infection. Their goal is to reduce disease severity and mortality rates through timely and effective treatment.

Problem

30% of mortality rate & causes 6 million deaths each year

€32 billion sepsis costs per year

Timely diagnosis and treatment are critical in managing sepsis

Complex diagnostic challenge

Solution

We have developed a new first-class in vitro cellular immunoassay that detects sepsis within the first hour of bloodstream infection.

Our patented method and kit identify immune activity biomarkers with a sensitivity 3 times greater than the leading competitor, PCT. Additionally, our diagnostic process is 10 times faster than pathogen identification.

Our biomarker can be detected as early as one hour after infection, significantly earlier than the current standard biomarker (PCT). This early detection will enable healthcare providers to initiate accurate treatment at an earlier stage, reducing disease severity and minimizing the need for antibiotics or other drugs.

Story

Enrique Hernández (CEO), during his Postdoctoral studies at Bellvitge Hospital in Barcelona, discovered the importance of analyzing the immune system to detect sepsis early. He recognized that traditional detection methods relied on clinical signs and symptoms, often indicating advanced disease.  Hernández’s research focused on endotoxin tolerance in the innate immune system, realizing that changes in gene expression and immunological profiles could provide valuable information for early sepsis detection. Inspired by this scientific insight, he founded Loop Diagnostics, developing a technology that analyzes these factors to enable accurate and timely sepsis diagnosis. Hernández’s innovation has significantly advanced the field of sepsis detection, providing healthcare professionals with a precise tool for early intervention and improved patient outcomes.

RoadMap

T1

N

2018

Loop Diagnostics SL Incorporation                            

T2

N

2019

Development of the first MVP                            

T3

N

2020

Clinical proof of concept with septic patients           

T4

N

2021

Patent application                                                

T5

N

2022

Development of the industrial prototype

T6

N

Q2 2023

Seed Round funding                                            

T7

N

Q3 2023

Industrial pilot production                                           

T8

N

Q4 2023

ISO13485 – QMS certification                            

T9

N

Q4 2023

Clinical trial results                                                       

T10

N

Q4 2023

Metodology and clinical trial Publications         

T11

N

Q1 2024

Technical File submitted for CE mar                         

T12

N

Q1 2024

UKCA mark                                                           

T13

N

Q2 2024

Initial sales in the UK                                                  

T14

N

Q4 2024

Obtaining the CE mark                                         

T15

N

Q4 2024

Cost-effective clinical trials                                         

T16

N

Q4 2024

Launch marketing activities to 2 European countries

T17

N

Q1 2025

Market penetration in the UK                                  

T18

N

Q1 2025

  FDA regulatory activities-De Novo                  

T19

N

Q4 2025

Market penetration in Europe                                     

T20

N

Q1 2026

Launch marketing activities in the USA          

icolab-mask-1
icolab-mask-1

Email

eduard@loopdx.com

Office

c. de Santander 45, Stage2
08020, Barcelona, Spain

Phone

+34 696 17 75 93

Follow

5 + 9 =

Products manufactured by Loop Diagnostics are in the process of obtaining certification of CE marking according to In Vitro Diagnostic Regulations as in vitro diagnostic devices. All pictures of products, packaging and product names disclosed in this website are of prototypes for displaying purposes. The final products are, however, currently unavailable for commercialization, only for research and performance evaluation purposes.

Accessibility Toolbar